Role of osteoprotegerin in vascular disorders of the end-stage renal disease patients

被引：8
|
作者：
Moldovan, Diana [1 ]
Kacso, Ina Maria [1 ]
Rusu, Crina [1 ]
Potra, Alina [1 ]
Bondor, Cosmina Ioana [2 ]
Moldovan, Ioan [3 ]
Patiu, Ioan Mihai [4 ]
Vladutiu, Dan [1 ]
Caprioara, Mirela Gherman [1 ]
机构：
[1] Univ Med & Pharm Iuliu Hatieganu, Dept Nephrol, Cluj Napoca, Romania
[2] Univ Med & Pharm Iuliu Hatieganu, Dept Stat, Cluj Napoca, Romania
[3] Emergency Mil Hosp, Cluj Napoca, Romania
[4] Nefromed Dialysis Ctr, Cluj Napoca, Romania
来源：
BIOMARKERS | 2015年 / 20卷 / 02期
关键词：
Cardiovascular disease; immunotoxicity; renal disease; CHRONIC KIDNEY-DISEASE; INTIMA-MEDIA THICKNESS; SERUM OSTEOPROTEGERIN; CARDIOVASCULAR EVENTS; FETUIN-A; ELEVATED OSTEOPROTEGERIN; CALCIFICATION INHIBITORS; PLASMA OSTEOPROTEGERIN; HEMODIALYSIS; ARTERY;
D O I：
10.3109/1354750X.2014.1000376
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Aim: To assess the osteoprotegerin (OPG) relationship with cardiovascular complications in hemodialysis (HD) patients. Methods: The study included 87 HD patients. Clinical characteristics, ankle-arm index (AAI), OPG and mineral markers levels were recorded. Arterial intimal calcification (AIC) and arterial medial calcification (AMC) were registered. Results: OPG levels were increased in HD patients. Patients with AIC (p = 0.006)/ AMC (p = 0.01) had higher OPG levels. OPG did not have any relation with cardiovascular diseases. OPG correlated positively with age, increased HD vintage and inversely with albumin and AAI. OPG has not been a risk factor for VC or cardiovascular disease. Conclusion: OPG rising could be a reaction in defense to vascular aggression, because OPG was associated with VC, but not with vascular disease.
引用
收藏
页码：116 / 122
页数：7
相关论文
共 50 条
  • [41] HCV in patients with end-stage renal disease
    Okoh, Emuejevoke J.
    Bucci, Jay R.
    Simon, James F.
    Harrison, Stephen A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (08): : 2123 - 2134
  • [42] The Impact of Diabetes Mellitus on Vascular Biomarkers in Patients with End-Stage Renal Disease
    Moon, Jeonggeun
    Lee, Chan Joo
    Lee, Sang-Hak
    Kang, Seok-Min
    Choi, Donghoon
    Yoo, Tae-Hyun
    Park, Sungha
    YONSEI MEDICAL JOURNAL, 2017, 58 (01) : 75 - 81
  • [43] Tuberculosis in patients with end-stage renal disease
    Fang, HC
    Lee, PT
    Chen, CL
    Wu, MJ
    Chou, KJ
    Chung, HM
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2004, 8 (01) : 92 - 97
  • [44] Correlates for end-stage renal disease patients
    Yavuz, N
    Karatas, M
    Kilinç, S
    SCANDINAVIAN JOURNAL OF CARING SCIENCES, 2000, 14 (03) : 179 - 183
  • [45] Hypertension in end-stage renal disease patients
    Zager, P
    Nikolic, J
    Raj, DSC
    Tzamaloukas, A
    Campbell, M
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2000, 9 (03): : 279 - 283
  • [46] Sleep disorders in patients with end-stage renal disease. Preliminary report
    Sieradzki, A.
    Okolow, T.
    Adamowski, T.
    Kiejna, A.
    Trafidlo, E.
    Weyde, W.
    Biecek, P.
    Morawska, N.
    EUROPEAN PSYCHIATRY, 2008, 23 : S280 - S281
  • [47] Sleep disorders in patients with end-stage renal disease undergoing dialysis therapy
    Merlino, G
    Piani, A
    Dolso, P
    Adorati, M
    Cancelli, I
    Valente, M
    Gigli, GL
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (01) : 184 - 190
  • [48] Sleep disturbances and breathing disorders in hypertensive patients with end-stage renal disease
    Sanner, B
    Zidek, W
    Tepel, M
    JOURNAL OF HYPERTENSION, 2003, 21 : S80 - S80
  • [49] Diagnostics and treatment of sleep disorders in end-stage renal disease patients on dialysis
    Sanner, B
    DIALYSE 1995, 1996, : 113 - 125
  • [50] Cardiovascular disease in end-stage renal disease patients
    Collins, AJ
    Li, SL
    Ma, JZ
    Herzog, C
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) : S26 - S29
12345